View Item 

Show simple item record

Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
dc.contributor.authorSaba, Nabil F.
dc.contributor.authorMendenhall, William M.
dc.contributor.authorHutcheson, Kate
dc.contributor.authorSuárez, Carlos
dc.contributor.authorWolf, Greg
dc.contributor.authorFerlito, Alfio
dc.date.accessioned2018-12-06T17:36:07Z
dc.date.available2020-01-06T16:40:59Zen
dc.date.issued2018-11-01
dc.identifier.citationSaba, Nabil F.; Mendenhall, William M.; Hutcheson, Kate; Suárez, Carlos ; Wolf, Greg; Ferlito, Alfio (2018). "Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?." Cancer 124(21): 4163-4164.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/146561
dc.publisherWiley Periodicals, Inc.
dc.titleSalvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines?
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146561/1/cncr31717_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146561/2/cncr31717.pdf
dc.identifier.doi10.1002/cncr.31717
dc.identifier.sourceCancer
dc.identifier.citedreferencePignon JP, le Maitre A, Maillard E, Bourhis J; MACH‐NC Collaborative Group. Meta‐analysis of chemotherapy in head and neck cancer (MACH‐NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4 ‐ 14.
dc.identifier.citedreferenceTan HK, Giger R, Auperin A, Bourhis J, Janot F, Temam S. Salvage surgery after concomitant chemoradiation in head and neck squamous cell carcinomas—stratification for postsalvage survival. Head Neck. 2010; 32: 139 ‐ 147.
dc.identifier.citedreferenceGalloway TJ, Zhang QE, Nguyen‐Tan PF, et al. Prognostic value of p16 status on the development of a complete response in involved oropharynx cancer neck nodes after cisplatin‐based chemoradiation: a secondary analysis of NRG Oncology RTOG 0129. Int J Radiat Oncol Biol Phys. 2016; 96: 362 ‐ 371.
dc.identifier.citedreferenceAng KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363: 24 ‐ 35.
dc.identifier.citedreferenceAng MK, Patel MR, Yin XY, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2011; 17: 6542 ‐ 6552.
dc.identifier.citedreferenceEsteller E, Vega MC, Lopez M, Quer M, Leon X. Salvage surgery after locoregional failure in head and neck carcinoma patients treated with chemoradiotherapy. Eur Arch Otorhinolaryngol. 2011; 268: 295 ‐ 301.
dc.identifier.citedreferenceHamoir M, Holvoet E, Ambroise J, Lengele B, Schmitz S. Salvage surgery in recurrent head and neck squamous cell carcinoma: oncologic outcome and predictors of disease free survival. Oral Oncol. 2017; 67: 1 ‐ 9.
dc.identifier.citedreferenceHo AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG. Decision making in the management of recurrent head and neck cancer. Head Neck. 2014; 36: 144 ‐ 151.
dc.identifier.citedreferenceKim J, Kim S, Albergotti WG, et al. Selection of ideal candidates for surgical salvage of head and neck squamous cell carcinoma: effect of the Charlson‐Age Comorbidity Index and oncologic characteristics on 1‐year survival and hospital course. JAMA Otolaryngol Head Neck Surg. 2015; 141: 1059 ‐ 1065.
dc.identifier.citedreferenceVermorken JB, Mesia R, Rivera F, et al. Platinum‐based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359: 1116 ‐ 1127.
dc.identifier.citedreferenceFerris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for recurrent squamous‐cell carcinoma of the head and neck. N Engl J Med. 2016; 375: 1856 ‐ 1867.
dc.identifier.citedreferenceBauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for platinum‐ and cetuximab‐refractory head and neck cancer: results from a single‐arm, phase II study. J Clin Oncol. 2017; 35: 1542 ‐ 1549.
dc.identifier.citedreferenceHarrington KJ, Ferris RL, Blumenschein G Jr, et al. Nivolumab versus standard, single‐agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health‐related quality‐of‐life results from a randomised, phase 3 trial. Lancet Oncol. 2017; 18: 1104 ‐ 1115.
dc.identifier.citedreferenceUppaluri R, Zolkind P, Lin T, et al. Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol. 2017; 35 ( 15 suppl ): 6012 ‐ 6012.
dc.identifier.citedreferenceWolf GT, Bellile E, Eisbruch A, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2017; 143: 355 ‐ 366.
dc.identifier.citedreferenceWuthrick EJ, Zhang Q, Machtay M, et al. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015; 33: 156 ‐ 164.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr31717_am.pdf
Size:
110.7KB
Format:
PDF
View/Open
Name:
cncr31717.pdf
Size:
75.78KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.